MediLexicon Logo
MediLexicon Logo
Abbreviations        Abbrev Definitions        Dictionary        ICD Codes        Equipment        Hospitals        Drugs        More..
  


Prandin

Company: Novo Nordisk
Approval Status: Approved December 1997
Treatment for: Type II diabetes
Areas: Diabetes / Endocrinology

| General Information | Clinical Results | Side Effects | Mechanism of Action |


General Information

Prandin (repaglinide) has been approved for the treatment of Type 2 diabetes. It is the first approved product in a new chemical class (meglitinide class) of orally administered drugs for the treatment of Type 2 diabetes, and was developed to manage meal related (prandial) glucose loads.


Clinical Results

In clinical trials, Prandin had its largest effect in the first two weeks. After that, patients were maintained at a dose that triggered response. There was an average reduction in hemoglobin A1c levels of 1.6 to 1.9 points.


Side Effects

Adverse events reported were comparable to sulfonylureas, but there was a slightly higher incidence of cardiovascular events when compared with glyburide.


Mechanism of Action

Prandin stimulates insulin secretion from the beta cells of the pancreas by binding to sites on the beta cell. Its quick onset and short duration of action concentrates its effect around meal time glucose load, which is important to the treatment of Type 2 diabetes. Prandin is minimally excreted by the kidney, which may be an advantage for patients who suffer from decreased kidney function.




< back to top

Prandin Drug Information

The Prandin drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.





MediLexicon International Ltd Logo

Privacy Policy   |    Disclaimer   |    Contact / Feedback

MediLexicon International Ltd
Bexhill-on-Sea, UK
MediLexicon International Ltd © 2004-2014 All rights reserved.